Medical-device maker NuVasive Inc. soared above peers in its sector Wednesday, jumping 9% after the company announced that its sales for 2013 and 2014 should be higher than previously expected.

NuVasive

NuVasive /quotes/zigman/92312/delayed /quotes/nls/nuva NUVA was up $3.02 to $36.80 a share after declaring that 2013 revenue should reach $683 million, up from its previous forecast of $670 million. That’s also more than the $670.6 million average prediction from analysts polled by FactSet.

A manufacturer of instruments used primarily in spinal surgeries, NuVasive now expects 2014 sales of $725 million, more than the $711.7 million FactSet average.

NuVasive also said its 2013 operating margin will exceed its own forecasts, but didn’t give a number.

NuVasive has scheduled its full-year and fourth-quarter earnings report for March 3.

Follow Russ Britt on Twitter @russbrittmktw

Follow Health Exchange on Twitter @MWHealthBlog

More health-care news from MarketWatch:

Intercept CEO says his drug could treat ‘next tsunami’ in liver disease

Pro-Obamacare stocks up 52% in the last year

Regeneron leads S&P after making presentation at conference